LXR agonists have been shown to promote β-cell proliferation and reduce β-cell apoptosis, suggesting potential therapeutic applications for improving glucose control and insulin production in individuals with T2DM [133]. This evidence concerns the gene INS and type 2 diabetes mellitus.